Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA BIOTECH SERVICES HOLDINGS LIMITED
中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT
STRATEGIC FRAMEWORK AGREEMENT WITH SUMITOMO HEAVY INDUSTRIES, LTD. IN RELATION TO LOCALIZATION OF BNCT EQUIPMENT IN CHINA

Building on the ongoing collaboration with Sumitomo on the BNCT accelerator system – NeuCure® (the world's first approved BNCT equipment), the Company has entered into the Framework Agreement with Sumitomo on 22 November 2026 to jointly localize procurement/production of consumables of NeuCure® in China.

Under the Framework Agreement, among other things, the Group shall establish the capability of procuring/producing and quality-inspecting consumables within China, and the localized supply function of the equipment's commonly used consumables shall be gradually transferred from Sumitomo to the Company.

The collaboration represents a strategic step in the Group's initiative to strengthen the BNCT ecosystem in China and will significantly enhance the cost competitiveness and delivery efficiency in the China market, thereby expanding the accessibility of BNCT therapy in China.

This announcement is made by China Biotech Services Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

Background

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 22 November 2026, the Company entered into a strategic framework agreement in relation to the localization of the equipment and consumables of boron neutron capture therapy ("**BNCT**") accelerator system - NeuCure® (the world's first approved BNCT equipment) in China (the "**Framework Agreement**") with Sumitomo Heavy Industries, Ltd. ("**Sumitomo**").

The Framework Agreement is a strategic framework arrangement setting out the objectives and scope of the cooperation regarding the localization of procurement/production of consumables and the domestic assembly of a portion of the BNCT equipment in China between Sumitomo (developer and manufacturer of NeuCure® and consumables) and the Company (exclusive authorized agent of Sumitomo's BNCT equipment in the China market).

Terms

Objectives of Cooperation

The objectives of the cooperation are to reduce the overall cost of BNCT equipment and its consumables in the China market; to enhance the cost-performance and relative competitiveness of the products; to shorten the equipment delivery cycle and spare parts response time; to improve localized after-sales service and maintenance capabilities; to accelerate the popularization and commercialization of BNCT therapy in China; and to realize a sustainable and compliant localized supply chain.

Localized procurement/production of consumables

The Company shall establish the capability of procuring/producing and quality-inspecting consumables within China, with the localized supply function of commonly used consumables gradually transferred from Sumitomo to the Company.

Domestic assembly of a portion of the BNCT equipment

The parties shall explore the feasibility and implementation path of assembling a portion of the BNCT equipment within the territory of China.

The scope of cooperation may be extended to the localization or joint research and development of other components.

The Framework Agreement is effective for an initial term of 2 years. It is non-legally binding in substance and subject to the execution of a final implementation agreement setting out the technical support, quality standards and regulatory registration arrangements.

Reasons for and Benefits of the Framework Agreement

The Company is the exclusive authorized agent of BNCT equipment - NeuCure® and its consumables manufactured by Sumitomo in the China market. Pengbo Hainan BNCT hospital, being the Group's flagship project located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China, commenced trial operations in February 2026, and began patient treatment for the first time in March 2026 with dozens of treatments completed to date.

The Framework Agreement represents a strategic step in the Group's initiative to strengthen the BNCT ecosystem in China. By progressively localizing the procurement / production of consumables and exploring domestic assembly of a portion of the BNCT equipment, the Group expects to significantly enhance cost competitiveness and delivery efficiency of BNCT equipment and consumables in the China market, thereby expanding the accessibility of BNCT therapy in China. This will accelerate the Group's positioning in the BNCT industry value chain and support the long-term growth of the BNCT business.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 23 November 2026

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.